Lintuzumab Ac-225

Drug Profile

Lintuzumab Ac-225

Alternative Names: 225Ac-HuM-195; 225Ac-lintuzumab; AC225 MOAB M195; Ac225 monoclonal antibody M195; Actimab-A; Actinium-225 (225Ac)-Lintuzumab; Actinium-225-labelled HuM195; HuM195-Ac-225; Lintuzumab-Ac225; SMART actinium-225-M-195

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator PDL BioPharma
  • Developer Actinium Pharmaceuticals; Baylor Research Institute; Memorial Sloan-Kettering Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD33 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I Multiple myeloma

Most Recent Events

  • 13 Dec 2016 Actinium Pharmaceuticals applies for Orphan Drug status in Acute myeloid leukemia in the EU
  • 01 Dec 2016 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater, Monotherapy) in USA (IV) (NCT02998047)
  • 14 Nov 2016 Actinium Pharmaceuticals receives notice of allowance from United States Patent and Trademark Office for lintuzumab Ac-225
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top